-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Every ischemic stroke represents a critical opportunity to prevent another, possibly more serious, stroke
Every ischemic stroke represents a critical opportunity to prevent another, possibly more serious, stroke
In a recent study published in JAHA, an authoritative journal in the field of cardiovascular disease, researchers performed a secondary analysis of the POINT (platelet-directed inhibition in patients with new-onset TIA and minor ischemic stroke) trial to assess serum serum levels prior to participation in the trial.
Blood vessel
Of the 4878 patients included in the study, 267 had recurrent stroke
Dual antiplatelet therapy was not associated with a reduced risk of subsequent stroke in hyperglycemic patients (HR, 1.
CONCLUSIONS: Hyperglycemia at presentation was associated with an increased risk of recurrent ischemic stroke following a high-risk transient ischemic attack or minor stroke
Hyperglycemia at presentation was associated with an increased risk of recurrent ischemic stroke following a high-risk transient ischemic attack or minor stroke
Original source:
Brian Mac Grory.
Hyperglycemia, Risk of Subsequent Stroke, and Efficacy of Dual Antiplatelet Therapy: A Post Hoc Analysis of the POINT Trial
Leave a Comment here
